|
Basic Characteristics of Mutations
|
|
Mutation Site
|
C480F |
|
Mutation Site Sentence
|
Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL97 |
|
Standardized Encoding Gene
|
UL97
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
AD169
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cytomegalovirus infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
Maribavir;Ganciclovir |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
33475730
|
|
Title
|
Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients
|
|
Author
|
Santos Bravo M,Plault N,Sanchez Palomino S,Mosquera Gutierrez MM,Fernandez Aviles F,Suarez Lledo M,Sabe Fernandez N,Rovira M,Alain S,Marcos Maeso MA
|
|
Journal
|
The Journal of infectious diseases
|
|
Journal Info
|
2021 Sep 17;224(6):1024-1028
|
|
Abstract
|
Two transplant recipients (1 kidney and 1 hematopoietic stem cell) received maribavir (MBV) after cytomegalovirus (CMV) infection clinically resistant to standard therapy. Both patients achieved CMV DNA clearance within 30 and 18 days; however, the UL97 C480F variant emerged, causing recurrent CMV infection after a cumulative 2 months of MBV and 15 or 4 weeks of ganciclovir treatment, respectively. C480F was not detected under ganciclovir before MBV treatment. Recombinant phenotyping showed that C480F conferred the highest level of MBV resistance and ganciclovir cross-resistance, with impaired viral growth. Clinical follow-up and genotypic and phenotypic studies are essential for the assessment and optimization of patients with suspected MBV resistance.
|
|
Sequence Data
|
-
|